Pharma major Cipla has announced that the company has received the final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).
Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr.The purpose of the Icatibant injection is for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
